▼ -18.28% Downside Potential
This price target is based on 3 analysts offering 12 month price targets for Prelude Therapeutics in the last 3 months. The average price target is $38.33, with a high forecast of $40.00 and a low forecast of $37.00. The average price target represents a -18.28% upside from the last price of $46.91.
The current consensus among 3 polled investment analysts is to hold stock in Prelude Therapeutics.
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2 for multiple genomically selected cancers; and PRT-K4 for solid tumors. Prelude Therapeutics Incorporated was founded in 2016 and is based in Wilmington, Delaware.